FcγR requirements leading to successful immunotherapy

Immunol Rev. 2015 Nov;268(1):104-22. doi: 10.1111/imr.12342.

Abstract

Monoclonal antibody (mAb) immunotherapy is currently experiencing an unprecedented amount of success, delivering blockbuster sales for the pharmaceutical industry. Having experienced several false dawns and overcoming technical issues which limited progress, we are now entering a golden period where mAbs are becoming a mainstay of treatment regimes for diseases ranging from cancer to autoimmunity. In this review, we discuss how these mAbs are most likely working and focus in particular on the key receptors that they interact with to precipitate their therapeutic effects. Although their targets may vary, their engagement with Fcγ receptors (FcγRs) on numerous immune effector cells is almost universal, and here we review their roles in delivering successful immunotherapy.

Keywords: FcγR; anti-CD20; antibody therapy; immunomodulation; immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Autoimmunity
  • Cytotoxicity, Immunologic
  • Gene Expression Regulation
  • Humans
  • Immunoglobulin G / immunology*
  • Immunoglobulin G / metabolism*
  • Immunomodulation
  • Immunotherapy*
  • Leukocytes / immunology
  • Leukocytes / metabolism
  • Mice
  • Neoplasms / immunology
  • Neoplasms / metabolism
  • Neoplasms / therapy
  • Protein Binding
  • Receptors, IgG / chemistry
  • Receptors, IgG / genetics
  • Receptors, IgG / metabolism*
  • Signal Transduction
  • Transplantation

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Receptors, IgG